主页 > 医学前沿 >
【drug-news】先声控股 博达药业Boda Pharmaceutical
Bicun is very important to Simcere. In Q2 of 2007, Bicun contributed 110 million RMB of revenue, one-third of the total sales of the company. That figure was up from 20% of revenue in the year earlier period. The sales of Bicun have ramped up quickly since its introduction: its revenues can boast a CAGR of 210% from 2004 to 2006. Simcere calls Bicun a “first-to-market, branded generic drug.” Edaravone has been investigated heavily in Japan for use as a neuroprotectant.
Simcere did not release revenue figures for Boda, but it did say the company was “fast-growing.” It produces injectable edaravone under the brand name Yidashen. Together the two companies will seek to increase the awareness of injectable edaravone in stroke patients, while they consolidate their rival sales networks.
When Simcere completed its IPO on the NYSE in April 2007, it proposed using a portion of the proceeds to make acquisitions. This is the first acquisition it has announced since the IPO. Simcere bought Endu, an innovative cancer drug, in 2006, prior to the IPO.
The company netted $162 million in the IPO, of which $53 million was left over after the amount initialed for debt reduction, R&D and new facilities 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 Simcere Pharmaceutical (SCR) of Nanjing paid 111 million RMB ($14.8 million) for a 51% stake in Boda Pharmaceutical, a company that markets a rival to Simcere’s best-selling drug, Bicun.
南京先声药业注资111亿人民币（合14.8亿美元）收购了博大药业51%的股份，博大药业对先声卖的最好的药---必存构成了市场竞争。
Bicun, an injected edaravone, is a neuroprotective drug.
必存是依达拉奉注射液，是一种神经保护药物。
It is administered following a stroke to protect organs during reperfusion (a return of blood supply following stroke).
中风后给予必存可以在缺血再灌注（中风后恢复血流供应）时保护器官。
Boda makes the only other injected edaravone available in China.
在中国，博大药业生产了唯一的另一种依达拉奉注射液。
Bicun is very important to Simcere.
必存对先声而言非常重要。
In Q2 of 2007, Bicun contributed 110 million RMB of revenue, one-third of the total sales of the company.
在2007年第二季度，必存的销售额是110亿人民币，占全公司销售额的三分之一。
That figure was up from 20% of revenue in the year earlier period.
这一数值比第一季度的20%又有所提高。
The sales of Bicun have ramped up quickly since its introduction: its revenues can boast a CAGR of 210% from 2004 to 2006.
必存引入先声后，销售额一路上升，从2004年到2006年增长了210%。
Simcere calls Bicun a “first-to-market, branded generic drug.” Edaravone has been investigated heavily in Japan for use as a neuroprotectant.
先声称必存为“市场第一，品牌的仿制药。” 在日本，对依达拉奉作为一种神经保护剂进行了大量研究。
Simcere did not release revenue figures for Boda, but it did say the company was “fast-growing.”
先声药业没有公布博大的收入，却提到博大药业“发展迅速”。
It produces injectable edaravone under the brand name Yidashen.
博大药业生产了商标名为Yidashen的依达拉奉注射液，
Together the two companies will seek to increase the awareness of injectable edaravone in stroke patients, while they consolidate their rival sales networks.
这两家公司会携手提高依达拉奉注射液在中风病人中的知名度，同时它们也要巩固已有的销售网络。
When Simcere completed its IPO on the NYSE in April 2007, it proposed using a portion of the proceeds to make acquisitions.
2007年4月先声药业在纽约证券交易所完成股票的首次公开发行时，就有人提议用一部分收益并购一些企业。
This is the first acquisition it has announced since the IPO. Simcere bought Endu, an innovative cancer drug, in 2006, prior to the IPO.
这次是先声药业上市后宣布的第一次并购。
Simcere bought Endu, an innovative cancer drug, in 2006, prior to the IPO.
先声在2006年上市之前就收购一个创新性的抗癌药：恩度。
The company netted $162 million in the IPO, of which $53 million was left over after the amount initialed for debt reduction, R&D and new facilities
公司在股票首次公开发行时募集到162亿美元，扣除最初的还债、研发、购买新设备的费用，还剩53亿美元。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-05-01 17:11
医学,生命科学网